T1	intervention 19 32	Goshajinkigan
T2	condition 42 52	neuropathy
T3	eligibility 56 101	breast cancer patients treated with docetaxel
T4	total-participants 322 327	Sixty
T5	intervention-participants 374 386	Thirty-three
T6	control-participants 458 460	27
T11	outcome 768 791	incidence of neuropathy
T12	iv-bin-percent 796 801	39.3%
T13	cv-bin-percent 824 829	88.9%
T14	outcome 875 890	grade 1 DEB-NTC
T15	iv-bin-abs 907 908	2
T16	outcome 916 923	grade 2
T17	iv-bin-abs 927 928	5
T18	outcome 939 946	grade 3
T19	iv-bin-abs 950 951	5
T20	outcome 959 974	Grade 1 NCI-CTC
T21	iv-bin-abs 991 992	7
T22	outcome 1000 1007	grade 2
T23	iv-bin-abs 1011 1012	6
T24	outcome 1024 1027	VAS
T25	outcome 1061 1086	grades 1, 2 and 3 DEB-NTC
T26	cv-bin-abs 1114 1116	12
T27	cv-bin-abs 1127 1129	12
T28	outcome 1155 1180	grades 1, 2 and 3 NCI-CTC
T29	cv-bin-abs 1198 1200	11
T30	cv-bin-abs 1208 1210	12
T31	cv-bin-abs 1221 1224	one
T32	cv-bin-abs 1104 1107	one
T33	outcome 1235 1238	VAS
T36	control 471 480	B12 group
T34	iv-cont-mean 1032 1035	2.7
T37	iv-cont-sd 1038 1041	2.2
T35	cv-cont-mean 1243 1246	4.9
T38	cv-cont-sd 1249 1252	2.4
